2019
DOI: 10.5414/cn109737
|View full text |Cite
|
Sign up to set email alerts
|

COL4A5 mutation causes Alport syndrome with focal segmental glomerulosclerosis lesion: Case report and literature review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2020
2020
2025
2025

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…Mutations in COL4A3 and COL4A4 are known to cause Alport syndrome (AS), a thin basement membrane nephropathy resulting in pathognomonic glomerular basement membrane, and secondary FSGS is known to develop in classic AS at later stages of the disease (45). For COL4A5, which may be affected by mutations causing AS with FSGS lesions (46), its expression was found to be shared between different cell subpopulations: podocytes, vascular smooth muscle cells, and mesangial cells. At the podocyte level, the application highlighted the specific expression of CRB2 (alias Crumbs Cell Polarity Complex Component 2), a family component of the Crumbs cell polarity complex known to be affected by mutations in FSGS (47).…”
Section: Online Results Visualization and The Development Of An Interamentioning
confidence: 99%
“…Mutations in COL4A3 and COL4A4 are known to cause Alport syndrome (AS), a thin basement membrane nephropathy resulting in pathognomonic glomerular basement membrane, and secondary FSGS is known to develop in classic AS at later stages of the disease (45). For COL4A5, which may be affected by mutations causing AS with FSGS lesions (46), its expression was found to be shared between different cell subpopulations: podocytes, vascular smooth muscle cells, and mesangial cells. At the podocyte level, the application highlighted the specific expression of CRB2 (alias Crumbs Cell Polarity Complex Component 2), a family component of the Crumbs cell polarity complex known to be affected by mutations in FSGS (47).…”
Section: Online Results Visualization and The Development Of An Interamentioning
confidence: 99%
“…Male patients with truncating mutations develop ESKD at approximately 20 years old, while those with non-truncating mutations develop ESKD at 40. It is worth noting that XLAS, caused by COL4A5 mutations, has considerable phenotypic heterogeneity and a combination of phenotypes (21)(22)(23)(24). It may not even show typical clinical phenotypes (such as hematuria, proteinuria, and hearing and vision problems) or AS-like pathological changes, which is not conducive to early diagnosis and effective intervention (11).…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, in young patients with unexplained glomerular diseases, without typical manifestations, clinicians also need to consider COL4A5 mutations. Genetic testing, based on next-generation sequencing, is crucial for the diagnosis of XLAS, which is a disease with high phenotypic and genetic heterogeneity (21)(22)(23)25).…”
Section: Discussionmentioning
confidence: 99%
“…Key components of its scaffolding are Collagen IV α3α4α5 trimers (Naylor et al, 2021). Alport syndrome is caused by mutations in the genes that encode these Collagen type IV alpha proteins ( COL4A3 , COL4A4 , and COL4A5 ) (Artuso et al, 2012; Barker et al, 1990; Cameron-Christie et al, 2019; Fallerini et al, 2014; Hadjipanagi et al, 2022; Heiskari et al, 1996; Hudson, 2004; Longo et al, 2006; Pokidysheva et al, 2021; Zhang et al, 2019). The mutations inhibit trimeric protein complex formation which prevents a pivotal developmental switch from Collagen type IV α1 and α2 isoforms in fetal kidney to the α3, α4, and α5 isoforms in mature podocytes (Harvey et al, 1998; Kalluri et al, 1997; Miner and Sanes, 1994).…”
Section: Introductionmentioning
confidence: 99%